Efficacy of helicobacter pylori eradication in Gastrointestinal side effects in patients with acute coronary syndrome

Efficacy of helicobacter pylori eradication in Gastrointestinal side effects of aspirin and clopidogrel in patients with acute coronary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014081814190N5

Enrollment

140

Registered

2014-09-06

Start date

2013-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome. Acute ischaemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: Amoxicillin 1 gram twice daily + Clarithromycine 500 mg twice daily + Pantoprazol 40 mg twice daily + Garlic daily. Intervention 2: Control group: Patients received

Treatment - Drugs

Intervention group: Amoxicillin 1 gram twice daily + Clarithromycine 500 mg twice daily + Pantoprazol 40 mg twice daily + Garlic daily

Control group: Patients received Pelasebo + Pantoprazol 40 mg twice daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients receiving the therapeutic regimen of aspirin and clopidogrel in acute coronary syndrome; positive Helicobacter pylori stool antigen test. Exclusion criteria: history of gastrointestinal bleeding; history of Helicobacter pylori eradication; pregnancy; cirrhosis; Patients with any medical history of any malignancy; history of peptic disease proven by endoscopy; acute or chronic renal failure; decompensated heart failure; other serious health conditions.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Gross gastrointestinal bleeding. Timepoint: Three months after the end of treatment. Method of measurement: using a questionnaire.	—

Secondary

Measure	Time frame
Dyspepsia. Timepoint: Three months after the end of treatment. Method of measurement: using a questionnaire.;Thrombotic events. Timepoint: Three months after the end of treatment. Method of measurement: using a questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Arman Shahriari

Ahvaz Jundishapur University of Medical Sciences

armanshahriari@yahoo.com+98 61 1336 7543

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026